Pharmaceuticals company Caplin Point Laboratories announced Q4FY23 & FY23 results: Total Revenue for FY23 grew by 16.4% YoY to Rs 1,523 crore Gross Margin for FY23 is at 54.8% EBITDA for FY23 is Rs 497 crore with EBITDA margins at 32.6% FY23 PAT is at Rs 377 crore up 22.2% YoY Cash and Cash equivalents at Rs 772 crore as of 31st March 2023; Capex for FY23 is at Rs 194 crore.; Free cash flow for the period is Rs 78 crore Receivables stood at 97 days as of 31st March 2023 Company finishes FY23 with strong top-line and bottom-line growth, supported by benchmark cashflows Caplin Steriles (US Injectable business) Total Revenue crosses Rs 213 crore in FY23 with 67% YoY growth; achieving PAT breakeven Capex projects of Caplin Steriles Phase 2, Caplin Onco and API unit at Vizag nearing completion Company’s liquid assets (Cash, inventory & receivables) are in excess of Rs 1,450+ crore Q4FY23 Revenue at Rs 400.68 crore, up 14.2 % YoY, as compared to Rs 350.75 crore in Q4FY22 PAT for the quarter is at Rs 101.24 crore up 25.2% as compared to Rs 80.83 crore in Q4FY22 Basic EPS grew by 25% to Rs 49.62 in FY23 against Rs 39.61 in FY22 Result PDF